References
- Gur C, Ilan Y, Shibolet O. Hepatic hydrothorax: pathophysiology, diagnosis and treatment. A review of the literature. Liver Int 2004; 24: 281–4
- Takahashi K, Chin K, Sumi K, Nakamura T, Matsumoto H, Niimi A, et al. Resistant hepatic hydrothorax; a successful case with treatment by nCPAP. Respir Med 2005; 99: 62–4
- Serrat J, Roza JJ, Planella T. Hepatic hydrothorax in the absence of ascites; respiratory failure in a cirrhotic patient. Anesth Analg 2004; 99: 1803–4
- Garcia, N, Jr, Mihas, AA. Hepatic hydrothorax: pathophysiology, diagnoses and management. J Clin Gastroenterol 2004;38:52–8.
- Pfamatter R, Quattropani C, Reichen J, Göke B, Wagner A C C. Treatment of hepatic hydrothorax and reduction of chest tube output with octreotide. Eur J Gastroenterol Hepatol 2001; 13: 977–80
- Nunez O, Garcia A, Rincon D, Alonso S, Echenagusia A, Banares R. Percutaneous intrahepatic portosystemic shunting as a treatment for refractory hepatic hydrothorax. Gastroenterol Hepatol 2002; 25: 143–7
- Cardenas A. Hepatorenal syndrome: a dreaded complication of end stage liver disease. Am J Gastroenterol 2005; 100: 460–7
- Dumortier J, Lepretre J, Scalone O, Boillot O, Scoazec JY, Delafosse B, et al. Successful treatment of hepatic hydrothorax with octreotide. Eur J Gastroenterol Hepatol 2000; 12: 817–20
- Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124: 1700–10
- Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulmonary Med 2003; 9: 261–5
- Gattoni A, Marotta F, Vangieri B, Pisani G, Cristiano F. Hepatorenal syndrome. Clin Ter 2004; 155: 375–89
- Ortega R, Gines P, Uriz J, Caerdenas A, Calahorra B, Heras DDL, et al. Terlipressin therapy with or without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study. Hepatology 2002; 36: 941–8
- Uriz J, Gines P, Cardenas A, Sort P, Jimenes W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43–8
- Therapondos G, Stanley AJ, Hayes PC. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study. J Gastroenterol Hepatol 2004; 19: 73–7
- Guevara M, Rodes J. Hepatorenal syndrome. Int J Biochem Cell Biol 2005; 37: 22–6
- Fierbinteanu-Braticevici C, Udeanu M, Usvat R, Andronescu D. The role of octreotide on renal function in patients with advanced cirrhosis. Rom J Intern Med 2004; 42: 173–81
- Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55–64
- Menteş BB, Kayhan B, Görgül A, Ünal S. Hepatic hydrothorax in the absence of ascites. Dig Dis Sci 1997; 42: 781
- Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100: 631–5